Funding to progress Chroma’s single-dose epigenetic modifying therapies and help growth of novel genetic medication platform designed to allow exact gene regulation whereas preserving genomic integrity

Financing led by GV, with participation from ARCH Enterprise Companions, DCVC Bio, Mubadala Capital, Sixth Road, and all current buyers

CAMBRIDGE, Mass., March 1, 2023 /PRNewswire/ — Chroma Drugs, Inc., (Chroma) a genomic medication firm pioneering single-dose epigenetic modifying therapeutics, right now introduced the completion of a $135 million Sequence B financing led by GV (Google Ventures), with participation from further new buyers ARCH Enterprise Companions, DCVC Bio, Mubadala Capital, Sixth Road, and all current buyers, together with Alexandria Enterprise Investments, Atlas Enterprise, Casdin Capital, Cormorant Asset Administration, Janus Henderson Traders, Newpath Companions, Omega Funds, Osage College Companions, Sofinnova Companions, T Rowe Worth, and Wellington Administration. The financing will help development of Chroma’s therapeutic applications towards the clinic, and continued funding within the firm’s core epigenetic modifying platform.

“Within the yr since launch, we’ve made important progress in advancing the pioneering work of our scientific founders in direction of harnessing the facility of the cell’s epigenome to manage gene expression and growing a sturdy portfolio of single-dose epigenetic modifying therapeutics,” stated Catherine Stehman-Breen, M.D., CEO of Chroma. “We’re grateful to this distinctive syndicate of buyers, whose dedication permits our ongoing drive to introduce this new class of precision genomic medicines with healing potential to sufferers with severe sicknesses.”

Present gene modifying approaches regulate gene expression by slicing or nicking DNA, introducing dangers related to leveraging unpredictable DNA restore pathways. Chroma’s single-dose epigenetic editors harness the cells’ innate mechanism for gene regulation to exactly and durably silence, activate, and multiplex genes utilizing a single platform, with out altering the underlying DNA sequence. This groundbreaking strategy permits Chroma to extra successfully tackle a variety of ailments and to focus on a number of pathways for complicated ailments.

“Epigenetic modifying opens the potential for pursuing targets on the genome beforehand intractable with different therapeutic modalities; this consists of the flexibility to focus on each protein coding and non-coding RNAs,” stated Vic Myer, Ph.D., CSO of Chroma. “Our strategy permits exact regulation whereas avoiding break-induced mutations, translocations, and rearrangements related to different applied sciences, eradicating limitations on the variety of simultaneous edits which can be attainable.”

“Genomic medication is an thrilling and fast-evolving area, and epigenetic modifying has emerged as a promising new frontier for gene regulation,” stated Issi Rozen, Enterprise Accomplice, GV. “Chroma’s know-how permits sturdy modulation of gene expression—each particular person genes and a number of genes directly—offering doubtlessly transformative remedies for sufferers residing with severe ailments.”

About Chroma Drugs

Chroma Drugs is a biotechnology firm pioneering a brand new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to ship exact, programmable single-dose therapeutics whereas preserving genomic integrity. The corporate was based by the world’s foremost consultants in genomic analysis and is led by a veteran crew of business leaders and scientists with deep expertise in genomic medication, drug discovery, and improvement. For extra data, please go to chromamedicine.com or comply with the corporate on LinkedIn and Twitter.

SOURCE Chroma Drugs